Overview

Efficacy of Misoprostol in Prevention of Neonatal Respiratory Morbidity in Parturient at Early Term Elective Caesarian Section

Status:
Active, not recruiting

Trial end date:
2021-03-01

Target enrollment:

Participant gender:

Summary

Neonatal respiratory morbidities represent a common group of post natal complications including respiratory distress syndrome, transient tachypnea of newborn, and persistent pulmonary hypertension of newborn. It is thought that preoperative vaginal misoprostol administration may decrease the incidence of neonatal respiratory morbidity especially transient tachypnea of newborn. And therefore, it may decrease the incidence of admission to neonatal intensive care units for respiratory causes.

Phase:

Phase 3

Details

Lead Sponsor:

Ain Shams University

Treatments:

Alprostadil
Misoprostol